Boditech Med

• Q2 2025 revenue of $30.74M (KRW 41.5B), up 14.5% YoY
• Operating profit of $6.81M (KRW 9.2B), up 13.9% QoQ; operating margin at 22.2%
• Double-digit growth in MENA and Latin America; notable rebound in Europe

Gangwon-do, Korea – August 8, 2025 – Boditech Med Inc. (CEO Eui-Yul Choi), a global point-of-care diagnostics company, today announced its preliminary consolidated financial results for the second quarter of 2025, reporting revenue of $30.74 million (KRW 41.5 billion) and operating profit of $6.81 million (KRW 9.2 billion). This represents a 14.5% year-on-year increase in revenue and a 0.7% year-on-year decrease in operating profit. Compared to the previous quarter, revenue grew by 6.2% and operating profit rose by 13.9%, with the operating margin improving to 22.2% from 20.7% in Q1.

Growth in Q2 was driven by strong performance across major global markets. The Middle East and North Africa (MENA) region posted a 29.3% increase in revenue, accounting for 25.5% of total sales and serving as a key growth engine. Latin America achieved rapid growth with a 38.6% increase, while Europe recorded a 5.9% increase, reflecting a clear recovery trend.

As of Q2 2025, revenue distribution by region was: MENA 25.5%, Europe 23.0%, Asia 18.6%, Latin America 14.3%, Africa 8.1%, and domestic (Korea) 7.3%, underscoring the company’s expanding global diversification.

By product category, non-communicable disease diagnostics showed notable growth. Cardiovascular products grew by 16.1%, diabetes diagnostics by 13.2%, and other disease categories by 49.5%, the highest growth rate. Hormone and infectious disease diagnostics remained steady, while cancer-related diagnostics maintained stable growth.

Boditech Med installed over 7,300 diagnostic instruments in the first half of 2025, equivalent to around 70% of the total installations in 2024 (10,552 units). In Q2 alone, 4,111 units were newly installed, including 2,623 units of its flagship AFIAS and ichroma™ series. While installation volumes surged during the pandemic and temporarily declined post-endemic, a robust recovery began in 2023, and 2025 is projected to mark a record-high in new installations.

CEO Eui-Yul Choi commented, “Our Q2 performance demonstrates the success of Boditech Med’s global market diversification and expanded product portfolio. The focus on high value-added products significantly contributed to improved profitability.” He added, “In the second half, we will intensify efforts to expand into new business areas such as clinical chemistry, hematology, and veterinary diagnostics, while strengthening quality competitiveness to penetrate developed markets.”